TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16925808
Drug: Cilostazol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100-200 mg/day)
Study: 10837300
Drug: Beta-carotene (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (42 mg all-trans-beta-carotene)
Study: 2871184
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (16 sessions of progressive relaxation, desensitization, and EMG biofeedback)
Study: 22940056
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of influenza vaccine
Study: 22940056
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of influenza vaccine
Study: 21575100
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mcg·kg(‐1) (F1 group)
Study: 21575100
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mcg·kg(‐1) (F2 group)
Study: 21575100
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg·kg(‐1) (K group)
Study: 21575100
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mcg·kg(‐1) plus Ketamine 0.5 mg·kg(‐1) (FK group)
Study: 18465334
Drug: Classical CMF
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical CMF (oral cyclophosphamide days 1-14, intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days)
Study: 18465334
Drug: Four-weekly intravenous
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-weekly intravenous CMF
Study: 18465334
Drug: Three-weekly intravenous
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-weekly intravenous CMF
Study: 17290563
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (80 mg elementary iron)
Study: 12847992
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Vitamin C
Study: 12847992
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Omega-3 fatty acids
Study: 12847992
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Vitamin C + 1 g Omega-3 fatty acids
Study: 11429120
Drug: rIFN‐gamma 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐gamma 0.05 mg/m(2) subcutaneously three times weekly for 48 weeks
Study: 7978409
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (EF), 10 micrograms/mL in saline
Study: 2929911
Drug: Morphine 0.5
Normalized name: morphine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.5 mg
Study: 19925723
Drug: Larval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval therapy (loose and bagged pooled)
Study: 19925723
Drug: Larval therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larval therapy
Study: 17174502
Drug: Barium sulphate
Normalized name: Barium sulphate
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium sulphate + iodinated hyperosmolar contrast agent (Gastrografin)
Study: 17174502
Drug: Barium sulphate
Normalized name: Barium sulphate
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium sulphate + both iodinated hyperosmolar contrast agent and effervescent granules
Study: 11860218
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 800 microg/daily b.i.d. (n = 66)
Study: 11860218
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 1000 microg/daily b.i.d. (n = 61)
Study: 29211620
Drug: quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: quadrivalent HPV vaccine (qHPV)
Study: 30261146
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (9vHPV and qHPV)
Study: 28923786
Drug: SYNERGY half-dose
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNERGY half-dose
Study: 27159854
Drug: Transnasal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 + GPC injection
Study: 27159854
Drug: Transnasal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal injection of 2 mL of 1% lidocaine + epinephrine 1:100,000 (monotherapy)
Study: 23928675
Drug: Topical nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nepafenac
Study: 20733445
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate
Study: 18215612
Drug: ximelagatran with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ximelagatran with aspirin
Study: 18215612
Drug: aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin alone (placebo)
Study: 10227004
Drug: 50 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/day 17 beta‐estradiol for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Study: 10227004
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 weeks, combined with oral medroxyprogesterone acetate 10 mg/day during the last 2 weeks
Study: 8929263
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (identical procedure but radio-frequency current not turned on)
Study: 1831505
Drug: Tetracycline (TC)
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline (TC) fiber therapy
Study: 1831505
Drug: Control fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control fiber (fibers without drug)
Study: 6181041
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with intradermal administration of methanol extraction residue of BCG (MER) and split course megavoltage radiotherapy (5,000 rad over 7 weeks)
Study: 30089135
Drug: Galantamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (both doses)
Study: 20170591
Drug: Natural grape
Normalized name: Walgreens Finest Natural Grapeseed 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural grape juice (18 ml/kg/day) for 1 month
Study: 20170591
Drug: Natural pomegranate
Normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural pomegranate juice (240 ml/day) for 1 month
Study: 10406247
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anesthesia with 2% tetracaine/14% benzocaine spray
Study: 2209278
Drug: Gentamicin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (3 mg/kg/day for five days) with metronidazole (1.5 gm)
Study: 31259738
Drug: Tenofovir (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir (1% gel)
Study: 31259738
Drug: Dapivirine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapivirine (25 mg in vaginal ring)
Study: 28937531
Drug: Intranasal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DEX (2 μg/kg)
Study: 12901592
Drug: Twinrix vaccine
Normalized name: TWINRIX vaccine 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix vaccine (0‐, 1‐, 6‐month vaccination schedule)
Study: 11051122
Drug: LEV 1500
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 1500 mg twice daily (monotherapy)
Study: 11051122
Drug: LEV 1500
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 1500 mg twice daily (add-on phase)
Study: 11051122
Drug: LEV 3000
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 3000 mg/d (add-on phase)
Study: 23913917
Drug: Self-administered, computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered, computer-assisted self-management
Study: 23913917
Drug: Self-administered program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered program with enhanced social support
Study: 22443839
Drug: Short family
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short family intervention with five weekly home‐based intervention sessions
Study: 8907403
Drug: Peer-led drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led drug prevention program
Study: 8907403
Drug: Adult-led drug
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult-led drug prevention program
Study: 573558
Drug: Bupivacaine mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine mixed with chloroprocaine (0.5 mg bupivacaine and 3 mg chloroprocaine)
Study: 573558
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (0.5 mg)
Study: 573558
Drug: Chloroprocaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine alone (3 mg)
Study: 9808683
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg three times daily
Study: 7447770
Drug: Once-a-day 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-a-day 0.25% timolol ophthalmic solution
Study: 7447770
Drug: Twice-a-day 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day 0.25% timolol ophthalmic solution
Study: 27956003
Drug: Anacetrapib 25
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 25 mg
Study: 23663521
Drug: Person-centred proactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person-centred proactive telephone support (daily for up to 14 days after hospital discharge)
Study: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 15 mg
Study: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 30 mg
Study: 16324916
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 45 mg
Study: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 15 mg plus Sulfonylurea (SU)
Study: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 30 mg plus Sulfonylurea (SU)
Study: 15140339
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 30 mg plus Metformin (MET)
Study: 11598535
Drug: LV5FU2 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LV5FU2 low dose
Study: 11598535
Drug: LV5FU2 high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 high dose
Study: 11598535
Drug: 5FU weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5FU weekly
Study: 11598535
Drug: Weekly 5FU
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 5FU
Study: 7593726
Drug: Moclobemide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (400 mg daily)
Study: 3719424
Drug: Bupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25% solution, 25 mg first dose, 10 ml, reinjections every hour for 10 mg)
Study: 3719424
Drug: 2-Chloroprocaine (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-Chloroprocaine (2% solution, 200 mg first dose, 10 ml, reinjections every 30 min for 80 mg)
Study: 31218738
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention to improve OAC prescription
Study: 31218738
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of OACs at admission
Study: 27460100
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days)
Study: 27460100
Drug: 14-day modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day)
Study: 27460100
Drug: Modified bismuth
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified bismuth quadruple therapy
Study: 24392946
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly 56.5 μg teriparatide
Study: 22569710
Drug: OCP +
Normalized name: Oral Contraceptive Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP + GnRH agonist
Study: 22569710
Drug: OCP +
Normalized name: Oral Contraceptive Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCP + GnRH antagonist
Study: 20332770
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg once daily for 28 days
Study: 20332770
Drug: placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily for 28 days
Study: 17383926
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin (BoNT) injections into the submandibular glands
Study: 17383926
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin (BoNT) injections into the parotid glands
Study: 17383926
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between submandibular and parotid injections
Study: 15709833
Drug: Other forms
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other forms of treatment (pharmacotherapy either alone or in combination with family therapy)
Study: 10422923
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled morphine
Study: 7766565
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g raw potato starch (550 g RS/kg)
Study: 7766565
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g pregelatinized potato starch (0 g RS/kg)
Study: 7766565
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g pregelatinized potato starch plus 20 g lactulose (670 g indigestible disaccharide/kg)
Study: 2288551
Drug: VT =
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VT = 12 ml/kg (group 1)
Study: 2288551
Drug: VT =
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VT = 6 ml/kg (group 2)
Study: 6969109
Drug: Cephalothin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin prophylaxis administered intraoperatively
Study: 6969109
Drug: Cephalothin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin prophylaxis administered both intraoperatively and postoperatively
Study: 31417058
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dose of ferrous sulphate (65 mg elemental iron)
Study: 31417058
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of ferrous sulphate (130 mg elemental iron)
Study: 28524699
Drug: Nifedipine CR
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine CR (80 mg)/candesartan (8 mg)
Study: 28524699
Drug: Amlodipine (10 mg)/candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg)/candesartan (8 mg)
Study: 20925019
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg for 6 days)
Study: 19951216
Drug: Purified red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified red clover (Trifolium pratense) isoflavone (86 mg/day) tablets
Study: 17294808
Drug: Trimetazidine tablets
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine tablets (two brands)
Study: 11703344
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) - 2 mg 17‐beta‐oestradiol and 1 mg norethisterone acetate
Study: 26971745
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shockwave therapy (rESWT)
Study: 25205381
Drug: Eyes Open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyes Open (EO) at 0.25 Hz (L)
Study: 25205381
Drug: Eyes Closed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyes Closed (EC) at 0.25 Hz (L)
Study: 18930568
Drug: Cilazapril alone
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril alone (ACE-inhibitor group; n = 30)
Study: 18930568
Drug: Steroid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid plus cilazapril (combination group; n = 33)
Study: 18930568
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (hazard ratio, 0.1; 95% CI, 0.014 to 0.946)
Study: 11235580
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus chemotherapy
Study: 11235580
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus brachytherapy and chemotherapy
Study: 6389147
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg metoclopramide
Study: 6389147
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg metoclopramide
Study: 6389147
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg metoclopramide
Study: 28632555
Drug: Manual Treatment
Normalized name: Pari Manual Interrupter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Treatment (MT)
Study: 28632555
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (LBP)
Study: 24954745
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg biweekly) and Docetaxel (20 mg/m² weekly) with Radiation Therapy (RT)
Study: 14747817
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine (0.15 mg/kg; maximum 10 mg)
Study: 14747817
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (0.5 mg/kg; maximum 30 mg)
Study: 11870177
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m² every 21 days)
Study: 11870177
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with carboplatin/paclitaxel until progression
Study: 11870177
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms received second-line weekly paclitaxel at 80 mg/m²/wk after progression
Study: 7738617
Drug: Group 4
Normalized name: Chlamydophila psittaci biogroup 4 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 (highest dose of IFN alpha three times per day)
Study: 2073645
Drug: Alinidine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (30 mg 3 times a day)
Study: 6465630
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of 95% ethanol in fruit juice
Study: 26253455
Drug: Terlipressin (TP)
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (TP) 1.3 μg/kg/h + Norepinephrine (NE)
Study: 25126874
Drug: Timed overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed overnight (8 hours) Urine Albumin (microalbumin) Excretion (UAE)
Study: 24014834
Drug: MitraClip therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip therapy
Study: 15735546
Drug: HRT administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT administered in patches
Study: 6626061
Drug: Fenoterol powder,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol powder, 200 mcg three times per day
Study: 29910042
Drug: Belimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab (10 mg/kg bodyweight, intravenous, given at day 0, 14, 28, and then every 4 weeks for a total of seven infusions)
Study: 17169012
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (MgSO4) 4 g solution (0.1 g/ml) infused over 30 minutes
Study: 10077917
Drug: Traditional intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional intensive therapy
Study: 28412986
Drug: CGA (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGA (600 mg)
Study: 28412986
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg CGA)
Study: 16461168
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment including high-velocity and low-amplitude manipulation, proprioceptive neuromuscular facilitation, ischemic compression of myofascial trigger points, and spinal rehabilitation exercises.
Study: 14767084
Drug: Desferrioxamine (DFX)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFX) at a dose of 40 mg/kg subcutaneously, 5 days/week